ViroPharma Announces Nine Abstracts Relating to Cinryze Data Presented at 30th Congress of the EAACI

ViroPharma Incorporated VPHM today announced that data relating to Cinryze® from nine accepted abstracts were presented as poster presentations at the 30th Congress of the European Academy of Allergy and Clinical Immunology, June 11 through 15, in Istanbul, Turkey. Of the nine posters, two contain new data and seven contain data previously presented at the 2010 International Scientific Conference of the World Allergy Organization, the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology, and the 2011 American Academy of Allergy Asthma & Immunology Annual Meeting. Cinryze is the first and only U.S. FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema, a rare, debilitating and potentially fatal disease. Currently, Cinryze is available only in the United States, and is not approved to treat acute angioedema attacks, for children with HAE, or for pre-procedural administration.